Mylan’s Generic Provigil Will Launch In August Under Teva Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The agreement allows Mylan on the market before Teva’s 180-day exclusivity rights for modafinil expire in late September. For Teva, the deal could be a way of appeasing the Federal Trade Commission’s anti-competition concerns over the wakefulness drug.